The trademark application Zeylicav was filed by Novo Nordisk A/S, a corporation established under the laws of the Kingdom of Denmark (the "Applicant"). The application was published for oppositions on April 25, 2023, and it was registered by office on August 2, 2023 without any oppositions.
The application was filed in Danish (English was selected as the second language).